To this regard, a recent observation has shown that in a melanoma cell, ERAP1 inhibition enhanced the predicted MHC-I binding affinity, reduced the presentation of sub-optimal long peptides and increased the presentation of many high-affinity 9–12 mers, suggesting that the baseline ERAP1 activity is destructive for many potential epitopes (32). Here, ERAP1 is linked to melanoma.